The Latin America, Middle East and Africa Obesity Intervention Devices Market should witness market growth of 7.0% CAGR during the forecast period (2023-2029).
Technology-related improvements made to these intragastric balloons include the incorporation of twin and triple balloons to stop device migration from the stomach to the intestines in the case of a balloon deflation, thereby lowering the risk of intestinal obstruction. Another important element driving market expansion is the population's increased preference for minimally invasive operations and growing awareness of these procedures, which is due to their quicker recovery times.
To stop neuronal activity among the brain and the stomach, a gastric stimulation system is surgically inserted into the belly. The electrodes receive electrical signals from a rechargeable electrical pulse generator, wire leads, and nerve electrodes. Patient charging and setting adjustments are both made possible through external controls.
Compared to other surgical methods for treating obesity, intragastric balloons have benefits. These benefits include a shorter hospital stay, no incision needed for intragastric balloon delivery, and the absence of any other issues like blood loss. A piece of the stomach is removed and bypassed with other surgical weight loss treatments like sleeve gastrectomy and gastric bypass. Patients choose non-surgical methods because there are many difficulties with surgical procedures, which increases the need for intragastric balloons.
Adult obesity rates in the UAE are around 27.8%, according to the National Health Survey 2017-2018. Concerns have been expressed about the nation's rising obesity rates, which are among the highest in the world. All age groups are at risk for the negative effects of obesity on their health. The increased rate may be attributed to fast food heavy in fat, unfavorable weather, and insufficient exercise. The general population's increasing obesity will raise the need for anti-obesity medications for treatment, opening up new market potential. It is anticipated that the prevalence of diabetes will increase, driving up market growth in the region.
The Brazil market dominated the LAMEA Obesity Intervention Devices Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $6 million by 2029. The Argentina market is poised to grow at a CAGR of 7.6% during (2023-2029). Additionally, The UAE market would showcase a CAGR of 6.7% during (2023-2029).
Based on End-user, the market is segmented into Hospitals and Clinics & Others. Based on Device, the market is segmented into Gastric Bands, Gastric Balloon and Gastric Stimulation System. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, Apollo Endosurgery, Inc. (Boston Scientific Corporation), ReShape Lifesciences, Inc., AbbVie, Inc., Allurion Technologies, Inc., Spatz FGIA, Inc, Cousin Surgery, A.M.I. GmbH, ENDALIS, and GI Dynamics, Inc.
Technology-related improvements made to these intragastric balloons include the incorporation of twin and triple balloons to stop device migration from the stomach to the intestines in the case of a balloon deflation, thereby lowering the risk of intestinal obstruction. Another important element driving market expansion is the population's increased preference for minimally invasive operations and growing awareness of these procedures, which is due to their quicker recovery times.
To stop neuronal activity among the brain and the stomach, a gastric stimulation system is surgically inserted into the belly. The electrodes receive electrical signals from a rechargeable electrical pulse generator, wire leads, and nerve electrodes. Patient charging and setting adjustments are both made possible through external controls.
Compared to other surgical methods for treating obesity, intragastric balloons have benefits. These benefits include a shorter hospital stay, no incision needed for intragastric balloon delivery, and the absence of any other issues like blood loss. A piece of the stomach is removed and bypassed with other surgical weight loss treatments like sleeve gastrectomy and gastric bypass. Patients choose non-surgical methods because there are many difficulties with surgical procedures, which increases the need for intragastric balloons.
Adult obesity rates in the UAE are around 27.8%, according to the National Health Survey 2017-2018. Concerns have been expressed about the nation's rising obesity rates, which are among the highest in the world. All age groups are at risk for the negative effects of obesity on their health. The increased rate may be attributed to fast food heavy in fat, unfavorable weather, and insufficient exercise. The general population's increasing obesity will raise the need for anti-obesity medications for treatment, opening up new market potential. It is anticipated that the prevalence of diabetes will increase, driving up market growth in the region.
The Brazil market dominated the LAMEA Obesity Intervention Devices Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $6 million by 2029. The Argentina market is poised to grow at a CAGR of 7.6% during (2023-2029). Additionally, The UAE market would showcase a CAGR of 6.7% during (2023-2029).
Based on End-user, the market is segmented into Hospitals and Clinics & Others. Based on Device, the market is segmented into Gastric Bands, Gastric Balloon and Gastric Stimulation System. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, Apollo Endosurgery, Inc. (Boston Scientific Corporation), ReShape Lifesciences, Inc., AbbVie, Inc., Allurion Technologies, Inc., Spatz FGIA, Inc, Cousin Surgery, A.M.I. GmbH, ENDALIS, and GI Dynamics, Inc.
Scope of the Study
By End-user
- Hospitals
- Clinics & Others
By Device
- Gastric Bands
- Gastric Balloon
- Gastric Stimulation System
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Johnson & Johnson
- Apollo Endosurgery, Inc. (Boston Scientific Corporation)
- ReShape Lifesciences, Inc.
- AbbVie, Inc.
- Allurion Technologies, Inc.
- Spatz FGIA, Inc
- Cousin Surgery
- A.M.I. GmbH
- ENDALIS
- GI Dynamics, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. LAMEA Obesity Intervention Devices Market by End-user
Chapter 4. LAMEA Obesity Intervention Devices Market by Device
Chapter 5. LAMEA Obesity Intervention Devices Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Johnson & Johnson
- Apollo Endosurgery, Inc. (Boston Scientific Corporation)
- ReShape Lifesciences, Inc.
- AbbVie, Inc.
- Allurion Technologies, Inc.
- Spatz FGIA, Inc
- Cousin Surgery
- A.M.I. GmbH
- ENDALIS
- GI Dynamics, Inc.
Methodology
LOADING...
